@article{dd8743a606be453c86cb9b96267ea84f,
title = "Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer",
abstract = "The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the IMpassion130 trial which showed PD-L1 expression was associated with a better outcome. Two large studies have been done assessing immune cell PD-L1 expression in lung cancer. Here, we reanalyze one of those studies, to show that, even with an easier scoring method, there is still only poor agreement between assays and pathologist for immune cell PD-L1 expression.",
keywords = "Atezolizumab, Immunohistochemistry, Non-small cell lung cancer, PD-L1, Triple-negative breast cancer",
author = "Rimm, {David L.} and Gang Han and Taube, {Janis M.} and Yi, {Eunhee S.} and Bridge, {Julia A.} and Flieder, {Douglas B.} and Robert Homer and Roden, {Anja C.} and Hirsch, {Fred R.} and Wistuba, {Ignacio I.} and Lajos Pusztai",
note = "Funding Information: This work was supported in part by funding the Yale SPORE in Lung Cancer (P50CA196530) and funds from the Yale Comprehensive Cancer Center (P30CA016359). Funding Information: This study was funded by Bristol-Myers Squibb in collaboration with the National Comprehensive Cancer Network Oncology Research Program and by the Breast Cancer Research Foundation. Publisher Copyright: {\textcopyright} 2019 The Author(s).",
year = "2019",
month = jun,
day = "13",
doi = "10.1186/s13058-019-1156-6",
language = "English (US)",
volume = "21",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central Ltd.",
number = "1",
}